title: A New SV2A Ligand for Epilepsy.
abstract: Since the 1970s, racetams have been in use as cognitive enhancers. Levetiracetam was discovered to have antiseizure activity in animal models and was then found to bind to SV2A in synaptic and endocrine vesicles. Brivaracetam, an analog of levetiracetam, was identified in a medicinal chemistry campaign with the objective of discovering analogs with higher affinity at racetam-binding sites and greater antiseizure potency.
authors: Department of Neurology, School of Medicine, University of California, Davis, Sacramento, CA 95817, USA. Electronic address: rogawski@ucdavis.edu.
authors: Michael A
authors: MA
authors: Rogawski
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry* / Q000378:metabolism / Q000627:therapeutic use; D001665:Binding Sites; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D006801:Humans; D000077287:Levetiracetam; D008024:Ligands; D008562:Membrane Glycoproteins / Q000737:chemistry*; D009419:Nerve Tissue Proteins / Q000737:chemistry*; D010889:Piracetam / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use; D011485:Protein Binding; D011487:Protein Conformation; D011760:Pyrrolidinones / Q000737:chemistry* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D008024:Ligands; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D011760:Pyrrolidinones; C076414:SV2A protein, human; D000077287:Levetiracetam; C482793:brivaracetam; D010889:Piracetam